Live attenuated oral cholera vaccines

References

• Albert MJ, Siddique AK, Islam MS et al. Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet341, 704 (1993).
   PubMed Web of Science ®Google Scholar
• Comstock LE, Maneval D Jr, Panigrahi P et al. The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect. Immun.63, 317–323 (1995).
   PubMedGoogle Scholar
• Safa A, Bhuiyan NA, Alam M, Sack DA, Nair GB. Genomic relatedness of the new Matlab variants of Vibrio cholerae O1 to the classical and El Tor biotypes as determined by pulsed-field gel electrophoresis. Clin. J. Microbiol.43, 1401–1404 (2005).
   Google Scholar
• Cholera vaccines: WHO position paper. Weekly Epidemiological Record76, 117–124 (2001).
   Google Scholar
• Gitelson S. Gastrectomy, achlorhydria and cholera. Isr. J. Med. Sci.7, 663–667 (1971).
   PubMedGoogle Scholar
• Merrell DS, Butler SM, Qadri F et al. Host-induced epidemic spread of the cholera bacterium. Nature417, 642–645 (2002).
   PubMed Web of Science ®Google Scholar
• Hartley DM, Morris JG, Smith DL. Hyperinfectivity: a critical element in the ability of V. cholerae to cause epidemics? PLoS. Med.3, e7 (2006).
   PubMed Web of Science ®Google Scholar
• Cash RA, Music SI, Libonati JP, Craig JP, Pierce NF, Hornick RB. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J. Infect. Dis.130, 325–333 (1974).
   PubMed Web of Science ®Google Scholar
• Cash RA, Music SI, Libonati JP, Snyder MJ, Wenzel RP, Hornick RB. Response of man to infection with Vibrio cholerae. Clinical I, serologic, and bacteriologic responses to a known inoculum. J. Infect. Dis.129, 45–52 (1974).
   PubMed Web of Science ®Google Scholar
• Barua D, Paguio AS. ABO blood groups and cholera. Ann. Hum. Biol.4, 489–492 (1977).
   PubMed Web of Science ®Google Scholar
• Harris JB, Khan AI, Larocque RC et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect. Immun.73, 7422–7427 (2005).
   PubMed Web of Science ®Google Scholar
• Ryan ET, Dhar U, Khan WA et al. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am. Trop J. Med. Hyg.63, 12–20 (2000).
   PubMed Web of Science ®Google Scholar
• Ryan ET, Calderwood SB. Cholera vaccines. J. Travel. Med.8, 82–91 (2001).
   PubMedGoogle Scholar
• Mekalanos JJ, Collier RJ, Romig WR. Enzymic activity of cholera toxin. II. Relationships to proteolytic processing, disulfide bond reduction, and subunit composition. J. Biol. Chem.254, 5855–5861 (1979).
   Google Scholar
• Gill DM, King CA. The mechanism of action of cholera toxin in pigeon erythrocyte lysates. J. Biol. Chem.250, 6424–6432 (1975).
   PubMed Web of Science ®Google Scholar
• Gill DM, Meren R. ADP-ribosylation of membrane proteins catalyzed by cholera toxin: basis of the activation of adenylate cyclase. Proc. Natl Acad. Sci. USA75, 3050–3054 (1978).
   PubMed Web of Science ®Google Scholar
• Taylor RK, Miller VL, Furlong DB, Mekalanos JJ. Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc. Natl Acad. Sci. USA84, 2833–2837 (1987).
   PubMed Web of Science ®Google Scholar
• Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, Levine MM. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J. Exp. Med.168, 1487–1492 (1988).
   Google Scholar
• Sun DX, Mekalanos JJ, Taylor RK. Antibodies directed against the toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant mouse experimental cholera model. J. Infect. Dis.161, 1231–1236 (1990).
   PubMed Web of Science ®Google Scholar
• Jonson G, Holmgren J, Svennerholm AM. Epitope differences in toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1. Microb. Pathog.11, 179–188 (1991).
   PubMed Web of Science ®Google Scholar
• Rhine JA,Taylor RK. TcpA pilin sequences and colonization requirements for O1 and O139 Vibrio cholerae. Mol. Microbiol.13, 1013–1020 (1994).
   PubMed Web of Science ®Google Scholar
• Iredell JR, Manning PA. Biotype-specific tcpA genes in Vibrio cholerae. FEMS Microbiol. Lett.121, 47–54 (1994).
   Google Scholar
• Pearson GD, Woods A, Chiang SL, Mekalanos JJ. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor. Proc. Natl. Acad. Sci. USA90, 3750–3754 (1993).
   Google Scholar
• Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science272, 1910–1914 (1996).
   PubMed Web of Science ®Google Scholar
• Miller VL, Mekalanos JJ. Synthesis of cholera toxin is positively regulated at the transcriptional level by ToxR. Proc. Natl Acad. Sci. USA81, 3471–3475 (1984).
   PubMed Web of Science ®Google Scholar
• Miller VL, Taylor RK, Mekalanos JJ. Cholera toxin transcriptional activator ToxR is a transmembrane DNA binding protein. Cell48, 271–279 (1987).
   PubMed Web of Science ®Google Scholar
• DiRita VJ, Mekalanos JJ. Periplasmic interaction between two membrane regulatory proteins, ToxR and ToxS, results in signal transduction and transcriptional activation. Cell64, 29–37 (1991).
   PubMed Web of Science ®Google Scholar
• Carroll PA, Tashima KT, Rogers MB, DiRita VJ, Calderwood SB. Phase variation in tcpH modulates expression of the ToxR regulon in Vibrio cholerae. Mol. Microbiol.25, 1099–1111 (1997).
   Google Scholar
• Hase CC, Mekalanos JJ. TcpP protein is a positive regulator of virulence gene expression in Vibrio cholerae. Proc. Natl Acad. Sci. USA95, 730–734 (1998).
   PubMed Web of Science ®Google Scholar
• Levine MM, Nalin DR, Rennels MB et al. Genetic susceptibility to cholera. Ann. Hum. Biol.6, 369–374 (1979).
   Web of Science ®Google Scholar
• Levine MM, Nalin DR, Craig JP et al. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. R. Soc. Trop. Med. Hyg.73, 3–9 (1979).
   PubMed Web of Science ®Google Scholar
• Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. Duration of infection-derived immunity to cholera. J. Infect. Dis.143, 818–820 (1981).
   PubMed Web of Science ®Google Scholar
• Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis.151, 236–242 (1985).
   PubMed Web of Science ®Google Scholar
• Mosley WH, Ahmad S, Benenson AS, Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull. World Health Organ.38, 777–785 (1968).
   PubMed Web of Science ®Google Scholar
• Mosley WH, Benenson AS, Barui R. A serological survey for cholear antibodies in rural East Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull. World Health Organ.38, 327–334 (1968).
   PubMed Web of Science ®Google Scholar
• Mosley WH, McCormack WM, Ahmed A, Chowdhury AK, Barui RK. Report of the 1966–1967 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population – the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull. World Health Organ.40, 187–197 (1969).
   PubMedGoogle Scholar
• Saha D, Larocque RC, Khan AI et al. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J. Infect. Dis.189, 2318–2322 (2004).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Svennerholm AM. Mechanisms of disease and immunity in cholera: a review. J. Infect. Dis.136, S105–S112 (1977).
   Web of Science ®Google Scholar
• Czerkinsky C, Svennerholm AM, Quiding M, Jonsson R, Holmgren J. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect. Immun.59, 996–1001 (1991).
   Web of Science ®Google Scholar
• Qadri F, Wenneras C, Albert MJ et al. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect. Immun.65, 3571–3576 (1997).
   PubMed Web of Science ®Google Scholar
• Qadri F, Jonson G, Begum YA et al. Immune response to the mannose-sensitive hemagglutinin in patients with cholera due to Vibrio cholerae O1 and O139. Clin. Diagn. Lab. Immunol.4, 429–434 (1997).
   Google Scholar
• Losonsky GA, Yunyongying J, Lim V et al. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun.64, 10–15 (1996).
   PubMed Web of Science ®Google Scholar
• Qadri F, Ryan ET, Faruque AS et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect. Immun.71, 4808–4814 (2003).
   PubMed Web of Science ®Google Scholar
• Asaduzzaman M, Ryan ET, John M et al. The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139. Infect. Immun.72, 4448–4454 (2004).
   PubMed Web of Science ®Google Scholar
• Ryan ET, Calderwood SB. Cholera vaccines. Clin. Infect. Dis.31, 561–565 (2000).
   PubMedGoogle Scholar
• Svennerholm AM, Jertborn M, Gothefors L, Karim AM, Sack DA, Holmgren J. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit–whole cell vaccine. Infect. J. Dis.149, 884–893 (1984).
   PubMed Web of Science ®Google Scholar
• Clemens JD, van Loon F, Sack DA et al. Biotype as determinant of natural immunising effect of cholera. Lancet337, 883–884 (1991).
   PubMed Web of Science ®Google Scholar
• Jertborn M, Svennerholm AM, Holmgren J. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit–O1/O139 whole cell cholera vaccine. Vaccine14, 1459–1465 (1996).
   PubMedGoogle Scholar
• Black RE, Levine MM, Clements ML, Young CR, Svennerholm AM, Holmgren J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun.55, 1116–1120 (1987).
   PubMed Web of Science ®Google Scholar
• Clemens JD, Harris JR, Sack DA et al. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. Infect. J. Dis.158, 60–69 (1988).
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, von SL et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet366, 44–49 (2005).
   PubMed Web of Science ®Google Scholar
• Glass RI, Steele AD. The value of cholera vaccines reassessed. Lancet366, 7–9 (2005).
   Google Scholar
• Trach DD, Clemens JD, Ke NT et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet349, 231–235 (1997).
   PubMed Web of Science ®Google Scholar
• Honda T, Finkelstein RA. Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin. Proc. Natl. Acad. Sci. USA76, 2052–2056 (1979).
   PubMed Web of Science ®Google Scholar
• Levine MM, Black RE, Clements ML et al. Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate. Dev. Biol. Stand.53, 59–65 (1983).
   PubMedGoogle Scholar
• Levine MM, Tacket CO. Recombinant live cholera vaccines. In: Vibrio cholerae and cholera: molecular to global perspectives. Wachsmuth IK, Blake PA, Olsvik O (Eds). American Society for Microbiology Press, Washington, D.C. USA 395–414 (1994).
   Google Scholar
• Levine MM, Kaper JB, Herrington D et al. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect. Immun.56, 161–167 (1988).
   PubMed Web of Science ®Google Scholar
• Mekalanos JJ, Swartz DJ, Pearson GD, Harford N, Groyne F, de Wilde M. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature306, 551–557 (1983).
   PubMed Web of Science ®Google Scholar
• Taylor R, Shaw C, Peterson K, Spears P, Mekalanos J. Safe, live Vibrio cholerae vaccines? Vaccine6, 151–154 (1988).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Nataro JP et al. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a δctxA δzot δace derivative of El Tor Ogawa Vibrio cholerae. J. Infect. Dis.168, 1536–1540 (1993).
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB, Herrington D et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet2, 467–470 (1988).
   PubMed Web of Science ®Google Scholar
• Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol. Lett.111, 15–21 (1993).
   PubMed Web of Science ®Google Scholar
• Kaper JB, Levine MM. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines. Res. Microbiol.141, 901–906 (1990).
   Google Scholar
• Cryz SJ Jr, Levine MM, Losonsky G, Kaper JB, Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect. Immun.60, 3916–3917 (1992).
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr, Levine MM, Kaper JB, Furer E, Althaus B. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine8, 577–580 (1990).
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Wasserman SS, O’Donnell S, Losonsky GA, Cryz SJ, Levine MM. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect. Immun.60, 4430–4432 (1992).
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB. Live oral vaccines against cholera: an update. Vaccine11, 207–212 (1993).
   Google Scholar
• Su-Arehawaratana P, Singharaj P, Taylor DN et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis.165, 1042–1048 (1992).
   PubMed Web of Science ®Google Scholar
• Suharyono Simanjuntak C, Witham N et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5–9-year-old Indonesian children. Lancet340, 689–694 (1992).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Nataro JP et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis.166, 837–841 (1992).
   PubMed Web of Science ®Google Scholar
• Migasena S, Pitisuttitham P, Prayurahong B et al. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect. Immun.57, 3261–3264 (1989).
   PubMed Web of Science ®Google Scholar
• Simanjuntak CH, O'Hanley P, Punjabi NH et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J. Infect. Dis.168, 1169–1176 (1993).
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Butron B, Seas C et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun.61, 3994–3997 (1993).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Cohen MB, Wasserman SS et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect. Immun.67, 6341–6345 (1999).
   PubMed Web of Science ®Google Scholar
• Kaper JB, Morris JG Jr, Levine MM. Cholera. Clin. Microbiol. Rev.8, 48–86 (1995).
   PubMed Web of Science ®Google Scholar
• Losonsky GA, Tacket CO, Wasserman SS, Kaper JB, Levine MM. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect. Immun.61, 729–733 (1993).
   PubMed Web of Science ®Google Scholar
• Lagos R, Fasano A, Wasserman SS et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis.180, 1709–1712 (1999).
   PubMed Web of Science ®Google Scholar
• Richie EE, Punjabi NH, Sidharta YY et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine18, 2399–2410 (2000).
   PubMed Web of Science ®Google Scholar
• Calain P, Chaine JP, Johnson E et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine22, 2444–2451 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Tacket CO, Losonsky G et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect. Immun.65, 3852–3856 (1997).
   PubMed Web of Science ®Google Scholar
• Kenner JR, Coster TS, Taylor DN et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J. Infect. Dis.172, 1126–1129 (1995).
   PubMed Web of Science ®Google Scholar
• Sack DA, Sack RB, Shimko J et al. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. J. Infect. Dis.176, 201–205 (1997).
   PubMed Web of Science ®Google Scholar
• Cohen MB, Giannella RA, Bean J et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect. Immun.70, 1965–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J. Infect. Dis.192, 573–579 (2005).
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Salam MA et al. Peru-15 Study Group. Peru-15, a live attenuated orts, toddlers and infants in Phase I/II clinical trials in Bangladesh. Presented at 40th US-Japan Cholera and other Bacterial Enteric Infections Joint Panel Meeting. Abstract 24. 107 (2005).
   Google Scholar
• Benitez JA, Garcia L, Silva A et al. Preliminary assessment of the safety and immunogenicity of a new CTXφ-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate. Infect. Immun.67, 539–545 (1999).
   PubMed Web of Science ®Google Scholar
• Garcia L, Jidy MD, Garcia H et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect. Immun.73, 3018–3024 (2005).
   PubMed Web of Science ®Google Scholar
• Thungapathra M, Sharma C, Gupta N et al. Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1 serotype inaba biotype E1 Tor and assessment of its reactogenicity and immunogenicity in the rabbit model. Immunol. Lett.68, 219–227 (1999).
   Google Scholar
• Liang W, Wang S, Yu F et al. Construction and evaluation of a safe, l ive, oral Vibrio cholerae vaccine candidate, IEM108. Infect. Immun.71, 5498–5504 (2003).
   PubMed Web of Science ®Google Scholar
• Qadri F, Svennerholm AM, Shamsuzzaman S et al. Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh. Infect. Immun.73, 6577–6583 (2005).
   Google Scholar
• Trach DD, Cam PD, Ke NT et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull. World Health Organ.80, 2–8 (2002).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Taylor RK, Losonsky G et al. Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection. Infect. Immun.66, 692–695 (1998).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Nataro JP et al. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J. Infect. Dis.172, 883–886 (1995).
   PubMed Web of Science ®Google Scholar
• Losonsky GA, Lim Y, Motamedi P et al. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139, specificity and relevance to immunity. Clin. Diagn. Lab. Immunol.4, 264–269 (1997).
   PubMedGoogle Scholar
• Waldor MK, Mekalanos JJ. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype. J. Infect. Dis.170, 278–283 (1994).
   PubMed Web of Science ®Google Scholar
• Coster TS, Killeen KP, Waldor MK et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet345, 949–952 (1995).
   PubMed Web of Science ®Google Scholar
• Butterton JR, Boyko SA, Calderwood SB. Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strains. Vaccine11, 1327–1335 (1993).
   PubMedGoogle Scholar
• Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect. Immun.65, 2941–2949 (1997).
   PubMed Web of Science ®Google Scholar
• Acheson DW, Levine MM, Kaper JB, Keusch GT. Protective immunity toShiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun.64, 355–357 (1996).
   Google Scholar
• Ryan ET, Butterton JR, Zhang T, Baker MA, Stanley SL Jr, Calderwood SB. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice. Infect. Immun.65, 3118–3125 (1997).
   PubMed Web of Science ®Google Scholar
• Butterton JR, Ryan ET, Acheson DW, Calderwood SB. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coliin Vibrio cholerae vaccine strains. Infect. Immun.65, 2127–2135 (1997).
   PubMedGoogle Scholar
• Butterton JR, Beattie DT, Gardel CL et al. Heterologous antigen expression in Vibrio cholerae vector strains. Infect. Immun.63, 2689–2696 (1995).
   Google Scholar
• Viret JF, Cryz SJ Jr, Favre D. Expression of Shigella sonnei lipopolysaccharide in Vibrio cholerae. Mol. Microbiol.19, 949–963 (1996).
   Google Scholar
• Viret JF, Cryz SJ Jr, Lang AB, Favre D. Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains. Mol. Microbiol.7, 239–252 (1993).
   Google Scholar
• Silva AJ, Mohan A, Benitez JA. Cholera vaccine candidate 638, intranasal immunogenicity and expression of a foreign antigen from the pulmonary pathogen Coccidioides immitis. Vaccine21, 4715–4721 (2003).
   Google Scholar
• Ryan ET, Crean TI, John M, Butterton JR, Clements JD, Calderwood SB. In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae. Infect. Immun.67, 1694–1701 (1999).
   PubMed Web of Science ®Google Scholar
• Ryan ET, Crean TI, Kochi SK et al. Development of a δglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect. Immun.68, 221–226 (2000).
   PubMed Web of Science ®Google Scholar
• John M, Crean TI, Calderwood SB, Ryan ET. In vitro and in vivo analyses of constitutive and in vivo-induced promoters in attenuated vaccine and vector strains of Vibrio cholerae. Infect. Immun.68, 1171–1175 (2000).
   Google Scholar
• Butterton JR, Ryan ET, Shahin RA, Calderwood SB. Development of a germfree mouse model of Vibrio cholerae infection. Infect. Immun.64, 4373–4377 (1996).
   PubMedGoogle Scholar
• Crean TI, John M, Calderwood SB, Ryan ET. Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains. Infect. Immun.68, 977–981 (2000).
   Google Scholar
• Clemens J, Jodar L. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Nat. Med. 11, S12–S15 (2005).
   Google Scholar
• deOnis M, Blossner M, Borghi E, Frongillo EA, Morris R. Estimates of global prevalence of childhood underweight in 1990 and 2015. JAMA291, 2600–2606 (2004).
   Google Scholar
• Clemens J, Rao M, Sack D et al. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines. Am. Epidemiol. J.142, 759–764 (1995).
   PubMed Web of Science ®Google Scholar
• Albert MJ, Qadri F, Wahed MA et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. Infect. J. Dis.187, 909–913 (2003).
   PubMed Web of Science ®Google Scholar
• Qadri F, Ahmed T, Wahed MA et al. Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine. Vaccine22, 416–421 (2004).
   PubMed Web of Science ®Google Scholar
• Rennels MB, Wasserman SS, Glass RI, Keane VA. Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children. US Rotavirus Vaccine Efficacy Group. Pediatrics96, 1132–1136 (1995).
   Google Scholar
• Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. Infect. J. Dis.174, S107–S111 (1996).
   PubMed Web of Science ®Google Scholar
• Cooper PJ, Chico M, Sandoval C et al. Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect. Immun.69, 1574–1580 (2001).
   PubMed Web of Science ®Google Scholar
• Cooper PJ, Chico ME, Losonsky G et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. Infect. J. Dis.182, 1199–1206 (2000).
   PubMed Web of Science ®Google Scholar
• Sack DA, Shimko J, Sack RB et al. Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers. Infect. Immun.65, 2107–2111 (1997).
   PubMed Web of Science ®Google Scholar
• Ortigao-de-Sampaio MB, Shattock RJ, Hayes P et al. Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS12, F145–F150 (1998).
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Gilks CF, Ojoo S et al. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS8, 779–785 (1994).
   PubMed Web of Science ®Google Scholar
• Eriksson K, Kilander A, Hagberg L, Norkrans G, Holmgren J, Czerkinsky C. Intestinal antibody responses to oral vaccination in HIV-infected individuals. AIDS7, 1087–1091 (1993).
   PubMed Web of Science ®Google Scholar
• Lucas ME, Deen JL, von SL et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med.352, 757–767 (2005).
   PubMed Web of Science ®Google Scholar
• Perry RT, Plowe CV, Koumare B et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull. World Health Organ.76, 63–71 (1998).
   PubMed Web of Science ®Google Scholar
• Goma Epidemiology Group. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994? No authors listed. Lancet345, 339–344 (1995).
   PubMed Web of Science ®Google Scholar
• Siddique AK, Salam A, Islam MS et al. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire. Lancet345, 359–361 (1995).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Potential use of oral cholera vaccines in emergency situations. Report of a meeting, Geneva, 12–13 May 1999, World Health Organization, Geneva, Switzerland WHO/CDS/CSR/EDC/99.4 (1999).
   Google Scholar
• World Health Organization. Cholera vaccines: a new public health tool? World Health Organization, Geneva, Switzerland WHO/CDS/CPE/ZFK/2004.5 (2004).
   Google Scholar
• Legros D, Paquet C, Perea W et al. Mass vaccination with a two-dose oral cholera vaccine in a refugee camp. Bull. World Health Organ.77, 837–842 (1999)
   PubMed Web of Science ®Google Scholar